TREATING PROGRESSIVE MULTIPLE SCLEROSIS

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG neuromyelitis optica spectrum disorder

Amy Kunchok, Charles Malpas, Petra Nytrova, Eva Kubala Havrdova, Raed Alroughani, Murat Terzi, Bassem Yamout, Jyh Yung Hor, Rana Karabudak, Cavit Boz, Serkan Ozakbas, Javier Olascoaga, Magdolna Simo, Franco Granella, Francesco Patti, Pamela McCombe, Tunde Csepany, Bhim Singhal, Roberto Bergamaschi, Yara Fragoso

2020-02-01

BACKGROUND: Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous sys..

The MSBase registry: Informing clinical practice

Tomas Kalincik, Helmut Butzkueven

2019-12-01

Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decision..

Risk of secondary progressive multiple sclerosis: A longitudinal study

Adam Fambiatos, Vilija Jokubaitis, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Raymond Hupperts, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci

2019-08-09

BACKGROUND: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly con..

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, Alessandra Lugaresi, Roberto Bergamaschi, Pierre Grammond, Raed Alroughani, Raymond Hupperts, Pamela McCombe, Vincent Van Pesch, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi

2019-01-15

IMPORTANCE: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a pha..

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Jordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, Raymond Hupperts, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Cristina Ramo-Tello, Maria Trojan, Mark Slee, Vahid Shaygannejad, Cavit Boz, Jeanette Lechner-Scott, Vincent Van Pesch, Eugenio Pucci

2018-11-01

IMPORTANCE: The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) ..

Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Jeannette Lechner-Scott, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Claudio Solaro, Francois Grand'Maison, Raymond Hupperts, Julie Prevost, Patrizia Sola, Diana Ferraro, Murat Terzi, Ernest Butler

2018-10-01

OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolim..

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Johannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, Guillermo Izquierdo, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Maria Trojano, Pierre Duquette, Marc Girard, Alexandre Prat, Francois Grand'Maison, Pierre Grammond, Eugenio Pucci, Cavit Boz, Patrizia Sola, Diana Ferraro, Daniele Spitaleri, Jeanette Lechner-Scott, Murat Terzi

2017-09-05

OBJECTIVE: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive mul..

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani

2017-09-01

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response var..

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Bernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, Eva Havrdova, Tomas Kalincik

2017-06-01

BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with im..

Data quality evaluation for observational multiple sclerosis registries

Tomas Kalincik, Jens Kuhle, Eugenio Pucci, Juan Ignacio Rojas, Magda Tsolaki, Carmen-Adella Sirbu, Mark Slee, Helmut Butzkueven

2017-04-01

OBJECTIVE: Objective and reproducible evaluation of data quality is of paramount importance for studies of 'real-world' observatio..

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard

2017-04-01

BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relap..

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, Jeannette Lechner-Scott, Mark Slee, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Pierre Grammond, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Eugenio Pucci, Roberto Bergamaschi, Celia Oreja-Guevara, Vincent Van Pesch

2017-03-01

OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple scle..

Contribution of different relapse phenotypes to disability in multiple sclerosis

Tamasine Stewart, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Vahid Shaygannejad, Raymond Hupperts, Raed Alroughani, Celia Oreja-Guevara, Eugenio Pucci, Cavit Boz, Jeannette Lechner-Scott

2017-02-01

Observational data: Understanding the real MS world

Tomas Kalincik, Helmut Butzkueven

2016-11-01

Randomised clinical trials are the primary source of evidence, guiding the use of disease-modifying drugs in multiple sclerosis. H..

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Raed Alroughani, Patrizia Sola, Cavit Boz, Eugenio Pucci, Jeanette Lechner-Scott

2016-09-01

Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS

Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond MM Hupperts, Cavit Boz

2016-04-01

BACKGROUND: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis..

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, Francois Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolanos, Marcela Fiol

2016-04-01

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatmen..

Defining reliable disability outcomes in multiple sclerosis

Tomas Kalincik, Gary Cutter, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Celia Oreja-Guevara, Cavit Boz, Eugenio Pucci, Roberto Bergamaschi, Jeannette Lechner-Scott

2015-11-01

Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Th..

Defining secondary progressive multiple sclerosis

J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, D Horakova, M Trojano, G Izquierdo, M Girard, P Duquette, A Prat, A Lugaresi, F Grand'Maison, P Grammond, R Hupperts, R Alroughani, P Sola, C Boz, M Terzi, E Pucci

2015-09-01

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja-Guevara, Roberto Bergamaschi, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernandez-Bolanos, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul

2015-08-01

BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been in..

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson

2015-03-01

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..

Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review

Tomas Kalincik

2015-01-01

Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple scleros..